The 2nd International Electronic Conference on Genes
11–13 Dec 2024
Human Genomics, Medical Genetics, Functional Genomics, Precision Medicine, Complex Disorders, Disease Gene Discovery
- Go to the Sessions
- A. Non-coding RNAs in Health and Diseases
- B. Single-cell RNA Sequencing
- C. Genetics and Genomics of Neurodegenerative Diseases
- D. Genetic Diagnosis and Targeted Therapy in Cancer
- E. Human Genomics and Genetic Diseases
- F. Technologies and Resources for Genetics Research
- G. Microbial Genetics and Genomics
- Event Details
Welcome from the Chair
It is with great enthusiasm that we announce the 2nd International Electronic Conference on Genes (IECGE2024). The conference is organized by the MDPI open access journal Genes (ISSN: 2073-4425; Impact Factor: 3.5) and will be held online from 11 to 13 December 2024.
This conference will provide leading scientists with an online platform to share their latest research and engage in exciting discussions. The main topics and sessions of the conference are:
- Non-coding RNAs in Health and Diseases;
- Single-cell RNA Sequencing;
- Genetics and Genomics of Neurodegenerative Diseases;
- Genetic Diagnosis and Targeted Therapy in Cancer;
- Human Genomics and Genetic Diseases;
- Technologies and Resources for Genetics Research;
- Microbial Genetics and Genomics.
In the virtual conference, there are additional advantages: (1) engagement tools that keep energy levels high, (2) participants are given a voice, (3) far stronger attention is received while one is talking, (4) a Q&A through the Chat is also possible if you do not wish to raise your question verbally, (5) polls, (6) feedback through the Chat, (7) the use of “Reaction” functions to show your voice, appreciation, or a request, (8) greater reach with remote audiences, and (9) the ability to deliver live and pre-recorded presentations simultaneously.
All the accepted abstracts will be available online on Sciforum.net during and after the conference.
Follow the conference organizer on Social Media
Department of Pathology, The University of Alabama at Birmingham, USA
Dr. Ponnazhagan is a trained molecular geneticist with a focus on cancer. He is currently a Full Professor and holds an Endowed Professorship in Experimental Cancer Therapeutics. The major research areas of Dr. Ponnazhagan’s lab are experimental cancer therapeutics, including stem cell and gene therapy using adeno-associated virus (AAV), tumor microenvironment (TME), and cancer bone metastasis. In reference to cancer-bone interaction, Dr. Ponnazhagan’s lab models breast cancer to adopt strategies that target tumor cells, immune suppression, and aggressive osteoclast functions. To overcome limitations in current therapies, his lab developed novel molecular tools and targeted delivery mechanisms, utilizing mesenchymal stem cells as effective therapeutic vehicles for bone remodeling in breast cancer osteolytic pathology. Towards targeting receptor activator of nuclear factor kappa-B ligand (RANKL) activation using osteoprotegerin (OPG), a decoy receptor for RANKL, without interfering in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of tumor cells, his lab developed an OPG mutant by structural protein engineering that lacks TRAIL binding affinity and validated in vivo in a disseminated osteolytic malignancy model. His group is the first one to identify a subset of immature myeloid cells, known as myeloid-derived suppressor cells, in the TME within the bone, directly undergo osteoclast differentiation and serve as osteoclast progenitors to enhance bone damage. Recent studies from his lab established the role of RANKL in activating M2 macrophages in breast cancer microenvironment and that dampening the effects of elevated RANKL using the OPG mutant resulted in a shift in the immune milieu favoring an anti-tumor cytokines and chemokine response.
Laboratory for Molecular Neuropsychiatry, Division of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia
Assoc. prof. Dubravka Svob Strac, PhD, works as a Head of the Laboratory for Molecular Neuropsychiatry, Department of Molecular Medicine, Ruder Boskovic Institute, Zagreb. She received her MSc and PhD degrees in Molecular Biology at the Faculty of Science, University of Zagreb, and MSc degree in Project Management at Baltazar University, Zapresic. In addition to scientific work (95 papers, 22 book chapters, 2271 citations; h-index 26, 30 projects), she teaches at the Universities of Zagreb, Rijeka and Osijek (mentor of 18 MSc and 5 PhD students). She received several stipends and awards, including awards from Ruder Boskovic Institute, Department of Biotechnology University of Rijeka, and Croatian National Science Award.
neuropsychiatry; genetics; biomarkers; neuropharmacology
Department of Human Sciences and Quality Life Promotion, San Raffaele Open University Rome and CEINGE Biotecnologie Avanzate, Naples, Italy
Thoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, USA
Dr. Gara is interested in exploring and identifying novel drug candidates and molecular pathways that are critical for initiation and progression of thoracic malignancies and eventually translate his research findings to develop new clinical trials in the branch that facilitate better outcomes for patients with these neoplasms. He employs wide varieties of techniques, methodologies and the state of art next generation sequencing in an induced pluripotent stem cell model of thoracic cancers. Additionally, he is passionate towards mentoring summer interns, postbacs and postdoctoral fellows in the branch.
cancer genetics; functional genomics; cell biology ;pharmacology ;structural biology immunotherapy
Faculty of Sciences and Technology, University of Coimbra, Calçada Martins de Freitas, Portugal
Isabel Henriques is an Associate Professor at the Department of Life Sciences, University of Coimbra, where she coordinates the PhD programme in Biosciences. She is a Researcher at the Centre for Functional Ecology, where she coordinates the Research Group One Health. Her area of specialization is Microbiology, and her research interests lie in Environmental Microbiology and Health. In the last decades she has been devoted to the study of antibiotic resistance ecology and of the role of microbiomes in the adaptation of organisms and ecosystems to global changes. She made important contributions to her field of research, published in 133 papers cited more than 5000 times. She is associate editor of BMC Genomics and Frontiers in Microbiology, and a member of the editorial board of Genes and Antibiotics.
One Health; Antimicrobial Resistance; Horizontal Gene Transfer; Environmental Microbiomes
B. Single-cell RNA Sequencing
C. Genetics and Genomics of Neurodegenerative Diseases
D. Genetic Diagnosis and Targeted Therapy in Cancer
E. Human Genomics and Genetic Diseases
F. Technologies and Resources for Genetics Research
G. Microbial Genetics and Genomics
The registration for IECGE 2024 will be free of charge! The registration includes attendance to all conference sessions.
If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for your understanding.
Please note that the submission and registration are two separate parts. Only scholars who registered can receive a link to access the conference live streaming. The deadline for registration is 6th December 2024.
Instructions for Authors
The 2nd International Electronic Conference on Genes will accept abstracts only. The accepted abstracts will be available online on Sciforum.net during and after the conference.
1. Deadline for abstract submission: 8 September 2024.
2. Deadline for abstract acceptance notification: 22 September 2024. You will be notified of the acceptance of an oral/poster presentation in a separate email.
Abstract submissions should be completed online by registering with www.sciforum.net and using the "New Submission" function once logged into the system. No physical template is necessary.
1. The structure abstract should include the introduction, methods, results, and conclusions sections of about 200–300 words in length.
2. All accepted abstracts will be published as one dedicated volume in Proceedings journal (ISSN: 2504-3900). If you wish to publish a full-length proceedings paper or a research article, please refer to the “Publication Opportunities” Section.
3. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
4. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
- Should include the title, authors, contact details and main research findings, as well as tables, figures and graphs where necessary.
- File format: PDF (.pdf).
- Size in pixel: 1,080 width x 1,536 height–portrait orientation.
- Size in cm: 38.1 width x 54.2 height–portrait orientation.
- Font size: ≥16.
We will reach out to you closer to the dates of the conference with more information.
Publication of the proceedings will be free of charge.
Authors are asked to disclose that it is a proceeding paper of the IECGE 2024 conference paper in their cover letter.
Proceedings submission deadline: 10 February 2025
Carefully read the rules outlined in the 'Instructions for Authors' on the journal’s website and ensure that your submission adheres to these guidelines.
Manuscripts for the proceedings issue must be formatted as follows:
Full author names.
Affiliations (including full postal address) and authors' e-mail addresses.
Results and Discussion.
Proceeding Paper Template
It is the authors' responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
To acknowledge the support of the conference's esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide six awards including Best Oral Presentation Awards and Best Poster Awards.
Number of Awards Available: 6
The Best Oral Presentation Awards are given to the submission judged to make the most significant oral contribution to the conference.
The Best Poster Awards are given to the submission judged to make the most significant and interesting poster for the conference.
There will be six winners selected for these awards. The winner will receive a certificate and 200 CHF each.
Sponsors and Partners
For information regarding sponsorship and exhibition opportunities, please click here.
Ms. Ann Li